Skip to main content
SpringerLink
Log in

Tumours in the Brain: A Special Case for Drug Delivery

  • Conference paper
Drug Delivery in Cancer Treatment III

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

  • 58 Accesses

Abstract

Brain tumours are not uncommon: primary tumours of the central nervous system account for 9% of all malignant diseases, and as much as 20% of all paediatric neoplasms [1]. On top of this can be added the tumours metastatic to brain, which may develop in 12%–40% of all patients with solid tumours [2], as well as a lower percentage for the haematological malignancies [3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Bleehen NM ed Tumours of the Brain. Springer-Verlag, Berlin 1986

    Google Scholar 

  2. Gamache FW Jr, Posner JB, Patterson RH Jr: Metastatic brain tumours. In: Youmans GR ed Neurological Surgery. Saunders, Philadelphia 1982 pp 2872–2898

    Google Scholar 

  3. Riehm H, Feickert HJ, Schrappe M, Henze G, Schellong G for the BFM Study Group: Therapy results in 5 ALL-BFM studies since 1970. Implications of risk factors for prognosis. In: Buchner T, Schellong G, Hiddemann W eds Acute leukaemias. Prognostic factors and treatment strategies. Springer, Berlin 1987 pp 71–75

    Google Scholar 

  4. Workman P: The pharmacology of brain tumour chemotherapy. In: Bleehen NM ed Tumours of the Brain. Springer-Verlag, Berlin 1986 pp 79–102

    Google Scholar 

  5. Greig NH: Optimizing drug delivery to brain tumours. Cancer Treat Rev 1987 14: 1–28

    Article  PubMed  CAS  Google Scholar 

  6. Greig NH: Chemotherapy of brain metastases: current status. Cancer Treat Rev 1984 11: 157–186

    Article  PubMed  CAS  Google Scholar 

  7. Bradbury MWB: The Concept of a Blood-Brain Barrier. Wiley, Chichester 1979

    Google Scholar 

  8. Rapoport SI: Blood-Brain Barrier in Physiology and Medicine. Raven Press, New York 1976

    Google Scholar 

  9. Suckling AJ, Rumsby MG, Bradbury MWB eds: The blood-brain barrier. In: Health and Disease. Ellis Norwood, Chichester 1986

    Google Scholar 

  10. Goldstein GW, Betz A: The blood-brain barrier. Sci Am 1986 255: 70–79

    Article  Google Scholar 

  11. Oldendorf WH: Blood-brain barrier permeability to drugs. Ann Rev Pharmacol 1974 14: 239–248

    Article  CAS  Google Scholar 

  12. Crone C: The blood-brain barrier; a modified tight epithelium. In: Suckling AJ, Rumsby MG, Bradbury MWB eds The Blood-Brain Barrier in Health and Disease. Ellis Norwood, Chichester 1986 pp 17–40

    Google Scholar 

  13. Reese TS, Karnovsky MJ: Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 1967 34: 207–217

    Article  PubMed  CAS  Google Scholar 

  14. Brightman MW, Reese TS: Junctions between intimately opposed cell membranes in the vertebrate brain. J Cell Biol 1969 40: 648–677

    Article  PubMed  CAS  Google Scholar 

  15. Reese TS, Feder N, Brightman MW: Electron microscopic study of the blood-brain and blood-cerebrospinal fluid barriers with microperoxidase. J Neuropath 1971 30: 137–138

    PubMed  CAS  Google Scholar 

  16. Janzer RC, Raff MC: Astrocytes induce bloodbrain barrier properties in endothelial cells. Nature 1987 325: 253–257

    Article  PubMed  CAS  Google Scholar 

  17. Dayson H: A comparative study of the aqueous tumour and cerebrospinal fluid in the rabbit. J Physiol 1955 129: 111–113

    Google Scholar 

  18. Dayson H, Kleeman CR, Levin E: The blood-brain barrier. In: Hogben AM, Lindgren P eds Drugs and Membranes. Pergamon, Oxford 1963 pp 71–94

    Google Scholar 

  19. Rall DP, Stabenau JR, Zubrod C: Distribution of drugs between blood and cerebrospinal fluid: general methodology and effect of pH gradients. J Pharmacol 1959 125: 185–193

    CAS  Google Scholar 

  20. Mayer SE, Maickel RP, Brodie BB: Kinetics of penetration of drugs and other foreign compounds into cerebrospinal fluid and brain. J Pharmacol 1959 127: 205–211

    CAS  Google Scholar 

  21. Brodie BB, Kurz H, Schanker LS: The importance of dissociation constant and lipid solubility in influencing the passage of drugs into the cerebrospinal fluid. J Pharmacol 1960 130: 20–25

    CAS  Google Scholar 

  22. Oldendorf WH, Hyman S, Braun L, Oldendorf SZ: Blood-brain barrier: penetration of morphine, codeine, heroin and methadone after carotid injection. Science 1972 178: 984–986

    Article  PubMed  CAS  Google Scholar 

  23. Levin VA: Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 1980 23: 682–684

    Article  PubMed  CAS  Google Scholar 

  24. Groothuis DR, Molnar P, Blasberg RG: Regional blood flow and blood-to-tissue transport in five brain tumor models. Prog Exp Tumor Res 1984 27: 132–153

    PubMed  CAS  Google Scholar 

  25. Brown JM, Workman P: Partition coefficient as a guide to the development of radiosensitisers which are less toxic than misonidazole. Radiat Res 1980 82: 171–190

    Article  PubMed  CAS  Google Scholar 

  26. Workman P: Lipophilicity and the pharmacokinetics of nitroimidazoles. In: Breccia A, Rimondi C, Adams GE eds Advanced Topics on Radiosensitizers of Hypoxic Cells. Plenum, New York 1982 pp 143–163

    Google Scholar 

  27. Bleehen NM, Grant RM, Jones DH, Roberts JT, Workman P, Gleave JRW, Hardy DG, Holmes AE: The penetration of misonidazole and desmethylmisonidazole into brain tumours and other central nervous system tumours in man. Br J Radiol 1983 56: 859–863

    Article  PubMed  CAS  Google Scholar 

  28. Roberts JT, Bleehen NM, Lee FYF, Workman P, Walton MI: A phase 1 study of the combination of benznidazole and CCNU in man. Int J Radiat Oncol Biol Phys 1984 10: 1745–1748

    Article  PubMed  CAS  Google Scholar 

  29. Roberts JT, Bleehen NM, Walton MI, Workman P: A clinical phase 1 toxicity study of Ro 03–8799:: plasma, urine, tumour and normal brain pharmacokinetics. Br J Radiol 1986 59: 107–116

    Article  PubMed  CAS  Google Scholar 

  30. Newman HFV, Bleehen NM, Ward R, Workman P: Hypoxic cell radiosensitisers in the treatment of high grade gliomas: a new direction using combined Ro 03–8799 pimonidazole and SR 2508 etanidazole. Int J Radiat Oncol Biol Phys 1988 15: 677–684

    Article  PubMed  CAS  Google Scholar 

  31. Ames MM, Powis G: Pharmacokinetics of nitrosoureas. In: Ames MM, Powis G, Kovach JS eds Pharmacokinetics of Anticancer Agents in Humans. Elsevier, Amsterdam 1983 pp 113–134

    Google Scholar 

  32. Egorin MJ, Kaplan RS, Salcman M, Aisner J, Colvin M, Wiernik PH, Bachur NR:. Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide. Clin Pharm Ther 1982 32: 122–128

    Article  CAS  Google Scholar 

  33. Levin VA, Freeman-Dove M, Landahl HD: Permeability characteristics of brain adjacent to tumours. Arch Neurol 1975 32: 785–791

    Article  PubMed  CAS  Google Scholar 

  34. Vick NA, Khanderkar JD, Bigner DD: Chemotherapy of brain tumors: the “blood-brain P. Workman barrier” is not a factor. Arch Neurol 1977 34: 523–526

    Article  PubMed  CAS  Google Scholar 

  35. Blasberg RG, Groothuis D, Molnar P: Applicationof quantitative autoradiographic measurements in experimental brain tumor models. Sem Neurol 1981 1: 203–221

    Article  Google Scholar 

  36. Blasberg RG, Kobayashi T, Patlack C, Shinohara M, Miyoaka M, Rice JM, Shapiro WR: Regional blood flow, capillary permeability, and glucose utilization in two brain tumour models: Preliminary observations and pharmacokinetic implications. Cancer Treat Rep 1981 65 Suppl 2:3–12

    PubMed  CAS  Google Scholar 

  37. Beaney RP: Functional aspects of human brain tumours as studied by position emission tomography. In: Bleehen NM ed Tumours of the Brain. Springer-Verlag, Beriin 1986 pp 63–82

    Google Scholar 

  38. Blasberg RG, Kobayashi T, Horowitz M, Rice JM, Groothuis D, Molnar P, Fenstermacher JD: Regional blood-to-tissue transport in ethylnitrosourea-induced brain tumors. Annal Neurol 1983 14: 202–215

    Article  PubMed  CAS  Google Scholar 

  39. Levin VA, Landahl HD, Freeman-Dove MA: The application of brain capillary permeability coefficient measurements to pathological conditions and the selection of agents which cross the blood-brain barrier. J Pharmacokinet Biopharm 1976 4: 499–519

    Article  PubMed  CAS  Google Scholar 

  40. Levin VA, Clancy TP, Ausman JI, Rall DP: Uptake and distribution of 3H-methotrexate by murine ependymoblastoma. J Natl Cancer Inst 1972 48: 875–883

    PubMed  CAS  Google Scholar 

  41. Levin VA, Chadwick M: Distribution of 5-fluorouracil-2-14C and its metabolites in a murine glioma. J Natl Cancer Inst 1972 49: 1577–1584

    PubMed  CAS  Google Scholar 

  42. Levin VA, Freeman-Dove MA, Maroten CE: Dianhydrogalactitol NSC-132 31 3: Pharmacokinetics in normal and tumour-bearing rat brain and antitumour activity against three intracerebral rodent tumours. J Natl Cancer Inst 1976 56: 535–539

    PubMed  CAS  Google Scholar 

  43. Stewart DJ, Benvenuto JA, Leavens M, Hall SW, Benjamin RS, Plunkett W, McCredie KB, Burgess MA, Loo TL: Penetration of 3-deazuridine into human brain, intracerebral tumour and cerebrospinal fluid. Cancer Res 1979 39: 4119–4122

    PubMed  CAS  Google Scholar 

  44. Stewart DJ, Leavens M, Friedman J, Benjamin RS, Moore EC, Bodey GP, Valdivieso M, Burgess MA, Wiseman C, Loo TL: Penetration of N-phosphonacetyl-L-aspartate into human central nervous system and intracerebral tumour. Cancer Res 1980 40: 3163–3166

    PubMed  CAS  Google Scholar 

  45. Stewart DJ, Leavens M, Maor M, Fenn L, Luna M, BonuraJ, Caprioli R, Loo TL, Benjamin RS: Human central nervous system distribution of cisdiamminedichloroplatinum and its use as a radiosensitizer in malignant brain tumours. Cancer Res 1982 42: 2474–2479

    PubMed  CAS  Google Scholar 

  46. Stewart DJ, Benvenuto JA, Leavens M, Smith RG, Cabanillas F, Benjamin RS, Loo TL: Human central nervous system pharmacology of pentamethylmelamine and its metabolites. J Neuro-Oncol 1983 1: 357–364

    Article  CAS  Google Scholar 

  47. Stewart DJ, Lu K, Benjamin RS, Leavens ME, Luna M, Yap H-Y, Loo TL: Concentrations of vinblastine in human intracerebral tumour and other tissues. J Neuro-Oncol 1983 1: 139–144

    CAS  Google Scholar 

  48. Stewart DJ, Richard MT, Hugenboltz H, Dennery J, Nundy D, Prior J, Montpetit V, Hopkins HS: Penetration of teniposide VM-26 into human intracerebral tumours. J Neuro-Oncol 1984 2: 315–324

    CAS  Google Scholar 

  49. Rosenblum MG, Stewart DJ, Yap BS, Leavens M, Benjamin RS, Loo TL: Penetrations of methylglyoxal bisguanylhydrazone into intracerebral tumors. Cancer Res 1981 41: 459462

    Google Scholar 

  50. Savaraj N, Lu K, Feun LG, Leavens MEL, Stewart D, Burgess MA, Benjamin RS, Loo TL: Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-biscarboethoxyamino1,4benzoquinone AZQ NSC-182986, J Neuro-Oncol 1983 1: 15–19

    Article  CAS  Google Scholar 

  51. Judson IR, Rutty CJ, Abel G, Graham MA: Low central nervous system penetration of N2,N4,N6,trihydroxymethyl-N2,N4,N6-trimethylmelamine Trimelamol: a cytotoxic S-triazine with reduced neurotoxicity. Br J Cancer 1986 53: 601–606

    Article  PubMed  CAS  Google Scholar 

  52. Horowitz M, Blasberg R, Molnar P, Strong J, Kornblith P, Pleasants R, Fenstermacher J: [14C] Misonidazole distribution in experimental RT-9 brain tumours. Cancer Res 1983 43: 3800–3807

    PubMed  CAS  Google Scholar 

  53. Yamamoto YL, Diksic M, Sako K: Pharmacokinetic and metabolic studies in human malignant glioma. In: Magistretti PL ed Functional Radionuclide Imaging of the Brain. Raven Press, New York 1983 pp 327–335

    Google Scholar 

  54. Levin VA, Patlack CS, Landahl HD: Heuristic modelling of drug delivery to malignant brain tumours. J Pharmacokinet Biopharm 1980 8: 257–296

    Article  PubMed  CAS  Google Scholar 

  55. Bleyer WA, Poplack DG: Clinical studies in the central nervous system pharmacology of methotrexate. In: Pinedo HM ed Clinical Pharmacology of Antineoplastic Drugs. Elsevier, Amsterdam 1978 pp 115–131

    Google Scholar 

  56. Fingert HJ, Hochberg FH: Megadose chemotherapy with bone barrow rescue. Prog Exp Tumor Res 1984 28: 67–78

    PubMed  CAS  Google Scholar 

  57. Mbidde EK, Selby PJ, Perren TJ, Dearnaley DP, Whitton A, Ashley S, Workman P, Bloom HJG, McElwain TJ: High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. Br J Cancer 1988 58: 779–782

    Article  PubMed  CAS  Google Scholar 

  58. Lee FYF, Workman P: Interaction of nitroimidazole sensitizers with drug metabolising enzymes–spectral and kinetic studies. Int J Radiat Oncol Biol Phys 1986 12: 1383–1387

    Article  PubMed  CAS  Google Scholar 

  59. Lee FYF, Workman P, Cheeseman KH: Misonidazole and benznidazole inhibit hydroxylation of CCNU by mouse liver microsomal cytochrome P-450 in vitro. Biochem Pharmac 1987 36: 1355–1355

    Google Scholar 

  60. Blasberg RG, Patlack C, Fenstermacher D: Intrathecal chemotherapy in brain tissue profiles after ventriculo-cisternal perfusion. J Pharmacol Exp Ther 1975 195: 73–83

    PubMed  CAS  Google Scholar 

  61. Collins JM: Pharmacokinetics of intraventricular administration. J Neuro-Oncol 1983 1: 283–291

    Article  CAS  Google Scholar 

  62. Stewart DJ: Novel modes of chemotherapy administration. Prog Exp Tumor Res 1984 28: 32–50

    PubMed  CAS  Google Scholar 

  63. Ushio Y, Hayakawa T, Mogami H: Uptake of tritiated methotrexate by mouse brain tumours after intravenous of intrathecal administration. J Neurosurg 1974 40: 706–716

    Article  PubMed  CAS  Google Scholar 

  64. Levitt M, Nixon PF, Pincus JH, Bertino IR: Transport characteristics of folates in cerebrospinal fluid, a study utilising doubly labelled 5-methyltetrahydrofolate and 5formyltetrahydrofolate. J Clin Invest 1971 50: 1301–1308

    Article  PubMed  CAS  Google Scholar 

  65. Spector R, Lorenzo AV: Folate transport in the central nervous system. Am J Physiol 1975 229: 777–782

    PubMed  CAS  Google Scholar 

  66. Tator CH, Wassenàar W: Intraneoplastic injection of methotrexate for experimental brain tumour chemotherapy. J Neurosurg 1977 46: 165–174

    Article  PubMed  CAS  Google Scholar 

  67. Bertino JR: Rescue techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate. Semin Oncol 1977 4: 203–216

    PubMed  CAS  Google Scholar 

  68. Fenstermacher J, Gazendam J: Intra-arterial infusions of drugs and hyperosmotic solutions as ways of enhancing CNS chemotherapy. Cancer Treat Rep 1981 65: 27–37

    PubMed  CAS  Google Scholar 

  69. Neuwelt EA: Therapeutic potential for blood-brain barrier modification in malignant brain tumour. Prog Exp Tumor Res 1984 28: 51–66

    PubMed  CAS  Google Scholar 

  70. Neuwelt E ed The Clinical Impact of the Blood-Brain Barrier and its Manipulation. Plenum Press, New York 1986

    Google Scholar 

  71. Griffin TW, Rasey JS, Bleyer WA: The effect of photon irradiation and blood-brain barrier permeability to methotrexate in mice. Cancer 1977 40: 1109–1111

    Article  PubMed  CAS  Google Scholar 

  72. Levin VA, Edwards MS, Byrd A: Quantitative observations of the acute effects of x-irradiation on brain capillary permeability I. Int J Radiat Oncol Biol Phys 1979 5: 1627–1631

    PubMed  CAS  Google Scholar 

  73. Workman P: Drug interactions with misonidazol:effects of dexamethasone and its derivatives on the pharmacokinetics and toxicity of misonidazole in mice. Biochem Pharmac 1980 39: 2769–2776

    Article  Google Scholar 

  74. Spigelman M, Zappulla R, Strauchen J, Feuer E, Johnson J, Holland J: Etoposide-induced blood-brain barrier disruption: duration of opening and histological sequelae. Cancer Res 1986 46: 1453–1457

    PubMed  CAS  Google Scholar 

  75. Spigelman M, Zappulla R, Malis L, Holland J: Intracarotid dehydrochlolate infusion: a new method for prolonged blood-brain barrier disruption. Neurosurgery 1983 12: 606–612

    Article  PubMed  CAS  Google Scholar 

  76. Hansch C, Smith N, Engle R, Wood H: Quantitative structure-activity relationships of antineoplastic drug: nitrosoureas and triazenoimidazoles. Cancer Treat Rep 1972 56: 443–456

    CAS  Google Scholar 

  77. Montgomery JA, Mayo JG, Hansch C: Quantitative structure-activity relationships in anticancer drugs. Activity of selected nitrosoureas against a solid tumour, the Lewis Lung carcinoma. J Med Chem 1974 17: 477–480

    Article  PubMed  CAS  Google Scholar 

  78. Levin VA, Kabra P: Effectiveness of the nitrosoureas as a function of their lipid solubility in the chemotherapy of experimental rat brain tumours. Cancer Treat Rep 1974 58: 875–883

    Google Scholar 

  79. Khan AH, Driscoll JS: Potential nervous system antitumour agents. Aziridinylbenzoquinones I. J Med Chem 1976 19: 313–317

    Article  PubMed  CAS  Google Scholar 

  80. Chou F, Khan AH, Driscoll JS: Potential nervous system anti-tumour agents. Aziridinylbenzoquinones II. J Med Chem 1976 19: 1302–1308

    Article  PubMed  CAS  Google Scholar 

  81. Workman P: Optimised treatment modalities for hypoxic tumour cells. In: Domellof L ed Drug Delivery in Cancer Treatment II. Symptom Control, Cytokines, Chemotherapy. Springer, Berlin 1989 pp 79–102

    Chapter  Google Scholar 

  82. Schilsky RL, Kelly JA, Ihde DC, Howzer DM, Cordes RS, Young RC: Phase 1 trial and pharmacokinetics of aziridinylbenzoquinone. Cancer Res 1982 42: 1582–1586

    PubMed  CAS  Google Scholar 

  83. Gormley P, Wood J, Poplack D: Ability of a new anticancer agent AZQ to penetrate the cerebrospinal fluid. Pharmacology 1981 22: 196–198

    Article  PubMed  CAS  Google Scholar 

  84. Johns D, Farquar D, Wolpert M, Chabner B, Loo T: Dialkylesters of methotrexate and 3,5dichloromethotrexate. Synthesis and interaction with aldelyde oxidase and dihydrofolate reductase. Drug Metab Dispos 1973 1: 580–589

    PubMed  CAS  Google Scholar 

  85. Rosowsky A, Abelson HT, Beardsley GP, Ensminger WD, Steele G, Modest EJ: Pharmacologic studies on the dibutyl and gmonobutyl esters of methotrexate in the rhesus monkey. Cancer Chemother Pharmac 1972 10: 55–61

    Google Scholar 

  86. Siegal CW, Macklin AW, Wooley JL: Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. Natl Cancer Inst Monogr 1987 5: 111–120

    Google Scholar 

  87. Greig NH, Rapaport SI: Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat. Cancer Chemother Pharmacol 1988 121: 1–8

    Google Scholar 

  88. Greig NH, Genka S, Daly E, Sweeney DJ, Rapoport SI: Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration. Cancer Chemother Pharmac 1990 25: 311–319

    Article  CAS  Google Scholar 

  89. Greig NH, Daly EM, Sweeney DJ, Rapoport SI: Pharmacokinetics of chlorambucil-tertiary butyl ester, a lipophilic chlorambucil derivative that achieves and maintains high concentrations in brain. Cancer Chemother Pharmac 1990 25: 320–325

    Article  CAS  Google Scholar 

  90. Newell D, Calvert A, Harrap K, McElwain T: Studies on the pharmacokinetics of chlorambucil and prednimustine in man. BrJ Clin Pharmac 1983 15: 253–258

    CAS  Google Scholar 

  91. Lee FYF, Coe P, Workman P: Pharmacokinetic basis for the comparative antitumour activity and toxicity of chlorambucil, phenyl acetic mustard and 8,8-difluorochlorambucil CB 7103 in mice. Cancer Chemother Pharmac 1986 17: 21–29

    Article  CAS  Google Scholar 

  92. Greig NH, Momma S, Sweeney DJ, Smith OR, Rapoport SI: Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. Cancer Res 1987 47: 1571–1576

    PubMed  CAS  Google Scholar 

  93. Adair C, McElnay J: Studies of the mechanism of gastrointestinal absorption of melphalan and chlorambucil. Cancer Chemother Pharmac 1986 17: 95–98

    Article  CAS  Google Scholar 

  94. Vistica D: Cellular pharmacokinetics of phenylalanine mustards. Pharmac Ther. 1983 22: 379–405

    Article  CAS  Google Scholar 

  95. Peng G, Marquex V, Driscoll J: Potential central nervous system antitumour agents: spirohydantoin mustard. J Med Chem 1975 18: 846–849

    Article  PubMed  CAS  Google Scholar 

  96. Rosenblum T, Stein A: Preferential distribution of diphenylhydantoin in primary brain tumours. Biochem Pharmac 1963 12: 453–454

    Article  Google Scholar 

  97. Plowman J, Lakings D, Owens E, Adamson R: Initial studies on the penetration of spirohyadantoin into the cerebrospinal fluid of dogs. Pharmacology 1977 15: 359–366

    Article  PubMed  CAS  Google Scholar 

  98. Rosenblum ML, Gerosa MA, Bodell WJ, Taicott RL: Tumor cell resistance. Prog Exp Tumor Res 1984 27: 191–214

    PubMed  CAS  Google Scholar 

  99. Knox RJ, Boland MP, Friedlos F, Coles B, Southan C, Roberts JJ: The nitroreductase enzyme in Walker cells that activates 5-aziridin1-yl-2,4-dinitrobenzamide CB 1954 to 5aziridin-1-yl-4-hydroxylamino-2-nitrobenzamide is a form of NADPH dehydrogenase quinone EC 1.6.99.2. Biochem Pharmac 1988 37: 4671–4677

    Article  CAS  Google Scholar 

  100. Schlager JJ, Powis G: Mitomycin C is not metabolized by but is an inhibitor of human kidney NADPH: quinone-acceptor oxidoreductase. Cancer Chemother Pharmacol 1988 22: 126–130

    Article  PubMed  CAS  Google Scholar 

  101. Workman P, Walton MI, Schlager JJ, Powis G: DT-Diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs? Br J Cancer 1989 60: 800–802

    Article  PubMed  CAS  Google Scholar 

  102. Walton MI, Workman P: Reductive metabolism of the novel indoloquinone EO9 by DT-diaphorase in vitro. Proc Am Assoc Cancer Res 1990 31: 398

    Google Scholar 

  103. Walton MI, Workman P: Enzymology of the reductive bioactivation of SR 4233: a novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochem Pharmac 1990 39: 1735–1742

    Article  CAS  Google Scholar 

  104. Cadoux-Hudson TAD, Blackledge MJ, Rajagopalan B, Taylor DJ, Radda GK: Human primary tumour metabolism in vivo: a phosphorous magentaic resonance spectroscopy study. Br J Cancer 1989 60: 430–436

    Article  PubMed  CAS  Google Scholar 

  105. Maxwell RJ, Workman P, Griffiths JR: Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo. Int J Radiation Oncol Biol Phys 1989 16: 925–929

    Article  CAS  Google Scholar 

  106. Chaplin DJ: Hydralazine-induced tumor hypoxia: A potential target for cancer chemotherapy. J Nat Cancer Inst 1989 81: 618–622

    Article  PubMed  CAS  Google Scholar 

  107. Adams GE, Stratford IJ, Nethersell ABW, White RD: Induction of severe tumor hypoxia by modifiers of the oxygen affinity of hemoglobin. ht J Radiat Oncol Biol Phys 1989 16: 1179–1182

    CAS  Google Scholar 

  108. Bodor N, Brewster M: Problems of drug delivery to the brain. Pharmac Ther 1982 19: 337–386

    Article  CAS  Google Scholar 

  109. Grossman S, Burch P, Brundrett R: Chlorambucil delivery and retention in brain using the specific chemical delivery system: a quantitative autoradiographic study. Proc Am Assoc Cancer Res 1988 29: 508

    Google Scholar 

  110. Weller RO: The immunopathology of brain tumours. In: Bleehen NM ed Tumours of the Brain, Springer-Verlag, Berlin 1986 pp 19–33

    Google Scholar 

  111. Bourdon MA, Coleman RE, Bigner DD: The potential of monoclonal antibodies as carriers of radiation and drugs for immunodetection and therapy of brain tumours. Prog Exp Tumor Res 1984 28: 79–101

    PubMed  CAS  Google Scholar 

  112. Schackert G, Simmons RD, Buzbee TM, Hume DA, Fidler IJ: Macrophage infiltration into experimental brain metastases: occurrence through an intact blood-brain barrier. J Natl Cancer Inst 1989 80: 1027–1034

    Google Scholar 

  113. Greig NH, Fredericks WR, Holloway HW, Soncrant TT, Rapoport SI: Delivery of interferon-alpha to brain by transient osmotic blood-brain barrier modification in the rat. J Pharmac Exp Ther 1988 245: 581–586

    CAS  Google Scholar 

  114. Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR: Multidrug-resistance gene P-glycoprotein is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989 86: 695–698

    Article  PubMed  CAS  Google Scholar 

  115. Coley HM, Twentyman PR, Workman P: Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug resistant cell lines, and further resistance modification by verapamil and cyclosporin A. Cancer Chemother Pharmacol 1989 24: 284–290

    Article  PubMed  CAS  Google Scholar 

  116. Coley HM, Twentyman PR, Workman P: Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem Pharmac 1989 38: 4467–4475

    Article  CAS  Google Scholar 

  117. Burt RK, Thorgeirsson SS: Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics. J Natl Cancer Inst 1988 80: 1383–1386

    Article  PubMed  CAS  Google Scholar 

  118. Stenning SP, Freedman LS, Bleehen NM: An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br J Cancer 1987 56: 89–90

    Article  PubMed  CAS  Google Scholar 

  119. Lee JS, Murphy WK, Glisson BS, Dhingra HM, Holoye PV, Hong WK: Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol 1989 7: 916–922

    PubMed  CAS  Google Scholar 

  120. Twelves CJ, Souhami RL, Harper PG, Ash CM, Spiro SG, Earl HM, Tobias JS, Quinn H, Geddes DM: The response of cerebral metastases in small cell lung cancer to systemic chemotherapy. Br J Cancer 1990 61: 147–150

    Article  PubMed  CAS  Google Scholar 

  121. Rustin JS, Newlands ES, Begent RHJ, Bagshawe KD: Weekly alternating etoposide, methotrexate and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol 1989 7: 900–903

    PubMed  CAS  Google Scholar 

  122. Rustin GJS, Newlands ES, Bagshawe KD, Begent RHJ, Crawford SM: Successful management of metastatic and primary germ cell tumours in the brain. Cancer 1986 57: 2108–2113

    Article  PubMed  CAS  Google Scholar 

  123. Rosner D, Nemoto T, Lane WW: Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986 58: 832–839

    Article  PubMed  CAS  Google Scholar 

  124. Folkman J: The vascularization of tumors. Sci American 1976 234 5: 59–73

    Article  Google Scholar 

  125. Long DM: Capillary ultrastructure in human metastic brain tumors. J Neurosurg 1979 51: 53–58

    Article  PubMed  CAS  Google Scholar 

  126. Long DM: Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. J Neurosurg 1970 32: 127–144

    Article  PubMed  CAS  Google Scholar 

  127. Wiestler O, Kleihues P, Pegg AE: O6Alkylguanine-DNA alkyltransferase activity in human brain and brain tumors. Carcinogenesis 1984 5: 121–124

    Article  PubMed  CAS  Google Scholar 

  128. Workman P: TCNU: a ray of hope for designer nitrosoureas? Eur J Cancer Clin Oncol 1987 23: 1823–1828

    Article  PubMed  CAS  Google Scholar 

  129. Yarosh DB, Hurst-Calderone S, Babich MA, Day RS: Inactivation of O6-methylguanine-DNA methyltransferase and sensitization of human tumor cells to killing by chloroethylnitrosourea by O6-methylguanine as a free base. Cancer Research 1986 46: 1663–1668

    PubMed  CAS  Google Scholar 

  130. Powis G, Hickman J, Workman P, Tritton TR, Abita J-P, Berdel WE, Gescher A, Moses HL, Nicolson GL: The cell membrane and cell signals as targets in cancer chemotherapy. Cancer Res 1990 50: 2203–2211

    Google Scholar 

  131. Workman P: The cell membrane and cell signals: new targets for novel anticancer drugs. Annals of Oncology 1990 1: 100–111

    PubMed  CAS  Google Scholar 

  132. Harsh GR, Keating MT, Escobedo JA, Williams LT: Platelet derived growth factor PDGF autocrine components in human tumor cell lines. J Neuro-Oncol 1990 8: 1–12

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MRC Clinical Oncology & Radiotherapeutics Unit, MRC Centre, Hills Road, Cambridge, CB2 2QH, UK

    Paul Workman

Authors
  1. Paul Workman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery, Örebro Medical Centre Hospital, 70185, Örebro, Sweden

    Lennart Domellöf

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Workman, P. (1990). Tumours in the Brain: A Special Case for Drug Delivery. In: Domellöf, L. (eds) Drug Delivery in Cancer Treatment III. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75938-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-75938-3_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-75940-6

  • Online ISBN: 978-3-642-75938-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation